Blood
Articles in this Issue
Machine learning using bayesian networks to predict response in patients with newly diagnosed Acute Myeloid Leukemia
Abstract Background: Acute myeloid leukemia (AML) is a hematopoietic stem cell malignancy characterized by clonal proliferation and reduced...
Targeted GvHD prophylaxis: Vedolizumab in the GvHD prevention regime with post-transplant cyclophophospamide, abatacept, calceneurin inhibitors in adults with hematologic disease: Result prospective study
Abstract Introduction Acute graft-versus-host disease (aGvHD) is a life-threatening complication of allogeneic hematopoietic stem cell trans...
Bridging the CART gap: Epcoritamab as a feasible option for relapsed/refractory DLBCL in CART-inaccessible regions - “the argentine experience”
Abstract Introduction:In the absence of CART,bispecific antibodies (BsAbs) emerged as a potential alternative for RR patients. BsAbs can off...
Impact of putative cell of origin on CD19+CAR-T outcomes in patients with large B-cell lymphoma
Abstract Background CAR-T therapy has demonstrated improved survival in patients with relapsed, refractory large B cell lymphoma (R/R LBCL)....
Promising results from an ongoing Phase I multicenter study of senti-202, a first-in-class, CD33 and/or FLT3 & not endomucin (EMCN), selective off-the-shelf logic gated CAR NK cell therapy in adults with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Abstract Despite recent improvements in treatment, R/R AML is associated with poor outcomes. Novel well-tolerated therapies that can lead to...
10-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 years: Long-term follow-up results of the randomized phase III trial AML21 of the EORTC leukemia group, GIMEMA and german MDS Study group
Abstract Background In older AML patients (pts), cure by allografting (HSCT) is often not achieved after standard, intensive chemotherapy (I...
Impact of short-form, case-based continuing medical education on clinician knowledge and competence in optimizing CAR T-cell therapy for Relapsed/Refractory multiple myeloma
Abstract Background: Emerging evidence underscores the pivotal role of immunotherapies targeting B-cell maturation antigen (BCMA) in improvi...
Combination anti-PD1 antibody and rituximab followed by R-CHOP for newly diagnosed DLBCL in elderly patients: Updated results of the phase II TREND trial
Abstract Background: Patients with diffuse large B-cell lymphoma (DLBCL) in the elderly face challenges in treatment due to comorbidities an...
Comparison of 80 mg/kg vs. 100 mg/kg post-transplant cyclophosphamide dose with flu/mel and allogeneic transplant: Less is not more
Abstract Background: Post-transplant cyclophosphamide (PTCy) with reduced-intensity conditioning for allogeneic hematopoietic cell transplan...
An unexpected role for maea in preventing ferroptosis of erythroblastic island macrophages to support erythropoiesis
Abstract The erythroblastic island (EBI), a functional unit consisting of a central macrophage surrounded by developing erythroid cells, was...
A novel and highly effective truncated BCMA safety switch for adoptive cell therapy
Abstract Introduction Adoptive cell therapies using engineered immune cells such as chimeric antigen receptor (CAR) T cells can be highly ef...
Association between soluble immune biomarkers and monoclonal gammopathy of undetermined significance (MGUS) in three large cancer epidemiology cohorts with participants from underrepresented groups.
Abstract Introduction: MGUS is a necessary (but not sufficient) precursor of multiple myeloma (MM), thus, examining determinants of MGUS may...
A multiarm phase 1b study of personalized oral maintenance therapy with decitabine/cedazuridine (ASTX727) plus physician's choice of venetoclax, gilteritinib, enasidenib, or ivosidenib in Acute Myeloid Leukemia
Abstract Introduction: Patients (pts) with acute myeloid leukemia (AML) who achieve remission but are unable to undergo hematopoietic stem c...
Identifying biological differences between two clinical risk groups of cutaneous CD30+ T cell lymphoproliferative disorders
Abstract Background Cutaneous CD30+ T cell lymphoproliferative disorders (CD30+ T LPD) comprise a group of diseases that...
A 10-year retrospective review of the effectiveness and safety of tranexamic acid in women with inherited bleeding disorders in the peripartum setting
Abstract Background: PPH occurs at a rate of nearly 11% globally and is a major cause of maternal mortality worldwide (Carroli, 2008.) Women...
Results from the first 200 ordered clinical modified ham (mHam) functional complement tests
Abstract The bioluminescent modified Ham (mHam) test was invented to help diagnose complement-mediated thrombotic microangiopathy (CM-TMA)/a...
Rheological effects of voxelotor in SCD: A double-edged sword?
Abstract Introduction. Blood viscosity—mainly determined by hematocrit (Ht) and red blood cell (RBC) rheological properties—is considered a...
Trends in transplantation for patients with myelodysplastic syndrome across recent decades: A registry-based study on behalf of the chronic malignancies working of the EBMT
Abstract Allogeneic hematopoietic cell transplantation (HSCT) remains the only curative treatment in patients with myelodysplastic syndrome...
Rebuilding immunity: Kinetics and clinical impact of immune reconstitution after CAR T-cell therapy in multiple myeloma
Abstract Introduction: Chimeric antigen receptor T-cell (CART) therapy frequently results in profound B- and T-cell depletion. The dynamics a...
Is there an optimal time to transition to low dose direct oral anticoagulants?
Abstract Background: Prophylactic-dose or low-dose apixaban and rivaroxaban have been studied in randomized controlled trials for the extend...
Gtb-3650 (anti-CD16/IL-15/anti-CD33) tri-specific killer engager (TriKE®) for the treatment of high risk myelodysplastic syndromes (MDS) and refractory/relapsed (R/R) Acute Myeloid Leukemia (AML) (NCT06594445)
Abstract Treatment of R/R AML and MDS remains an unmet clinical need. We have previously demonstrated the efficacy of haploidentical NK cell...
Fludarabine pharmacokinetics and dynamic immune monitoring as predictive biomarkers for CD19 and BCMA CAR-T
Abstract Introduction: The optimal use of fludarabine-based lymphodepletion (LD) and the requisite degree of lymphopenia for chimeric antige...
Co-mutation of BCOR and BCORL1 was associated with favorable outcome in the adverse risk patients with Acute Myeloid Leukemia
Abstract Introduction Mutations in BCOR (BCL6 corepressor) and its homolog BCORL1 (BCL6 corepressor-like 1) are closely associated with the p...
Enhancing hematology education through structured case-based learning and formal assessment: An approach to address learning gaps in clinical training
Abstract Background: Traditional hematology-oncology clinical education relies heavily on bedside rounds and case discussions. Contemporary...
TCA cycle turning is dispensable In Vivo and its loss promotes stem cell function during regeneration
Abstract In 1937, Krebs discovered that nutrients are oxidized by the conversion of 6-carbon citrate to 4-carbon oxaloacetate, followed by t...